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Background: Patients with juvenile-onset Systemic Lupus Erythematosus (JSLE) 
experience more severe disease when compared to individuals with adult-onset disease. 
Despite differences in phenotypes and pathogenesis between age groups, treatment is 
based upon adult trials. We compared treatment response and outcomes in JSLE-
associated lupus nephritis (LN) patients treated with mycophenolate mofetil (MMF) or 
intravenous cyclophosphamide (IVCYC). 
 
Methods: UK JSLE Cohort Study participants with class III or IV LN were included, 
measuring treatment response, damage accrual, time to inactive disease and/or 
subsequent flare. Mann-Whitney U, Fisher’s exact and Chi-squared tests utilised. 
 
Results: 34/51(67%) received MMF and 17/51(33%) IVCYC. No significant differences 
in renal-BILAG scores, urine albumin/creatinine ratio, serum creatinine, ESR, anti-
dsDNA-antibody, C3-levels, patient/physician global scores and prednisolone dosage 
were identified at 4-8, 10-14 months, and last follow-up. Standardised Damage Index 
scores did not differ between groups at 13 months, or last follow-up. Inactive LN was 
attained 8.5[4.5–12.6] months after MMF treatment, and 4.9[3.8-9.8] months following 
CYC (p=0.17). Time to renal flare was 14.5[5.1-40.8] months for MMF, and 11.1[6.4-
20.5] months for CYC (p=0.47).  
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Conclusion: This is the largest study to date investigating induction treatments for 
proliferative LN in children, demonstrating comparability of MMF and IVCYC. Future 
randomized prospective studies are needed. 
 
Keywords: Systemic Lupus Erythematosus, Lupus Nephritis, JSLE, SLE, Mycophenolic 
Acid, MMF, Cyclophosphamide. 
 
Word count: 2597  
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Introduction 
Juvenile-onset systemic lupus erythematosus (jSLE), also known as childhood-onset 
SLE, comprises approximately 15-20% of all systemic lupus erythematosus (SLE) cases. 
The underlying molecular pathophysiology, clinical presentations, and disease outcomes 
vary between JSLE and adult-onset SLE, with JSLE patients displaying a more aggressive 
disease course 1-3, including more renal involvement. Up 80% of JSLE patients develop 
Lupus Nephritis (LN) 1, compared with 40-50% of adult SLE patients 4, 5.  Overall, JSLE 
patients exhibit higher mean SLE disease activity index (SLEDAI) scores at diagnosis 
and over their disease course 2, 4, 5. Furthermore, JSLE patients require more aggressive 
treatment, including greater corticosteroid and immunosuppressive treatment burden over 
time 2, 4, 5, and lastly experience more rapid accrual of disease related damage as compared 
to adult SLE cohorts 2, 5, 6. 
 
Despite distinct differences in the phenotype and pathogenesis of JSLE 7, international 
recommendations for the treatment of JSLE 8 and juvenile LN specifically 9, are largely 
based upon data arising from clinical trials and observations in adult-onset SLE patients. 
As a consequence, head-to-head comparisons of induction treatments for proliferative, 
class III/IV International Society of Nephrology/Renal Pathology Society (ISN/RPS) LN 
in children are lacking. The largest paediatric study available retrospectively compared 
renal outcomes from seven patients treated with intravenous cyclophosphamide (IVCYC) 
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and six individuals treated with mycophenolate mofetil (MMF) 10. This demonstrated a 
non-statistically significant trend towards more MMF treated patients achieving LN 
remission at six months. A randomized, open-label, non-inferiority trial including 140 
North American adult SLE patients, suggested MMF to be more effective when compared 
to IVCYC 11. Notably, in this study 56% of patients included were of Black race, and 
17% were White. A further study including 370 adult SLE patients did not detect 
significant differences in renal response rates between patients receiving IVCYC vs. 
MMF for induction treatment 12. A recent meta-analysis of available randomized trials in 
adults with LN (including 4,222 participants across 53 studies), demonstrated MMF, 
calcineurin inhibitors, or their combination to be most effective for inducing LN 
remission in adults, as compared to IVCYC 13.  
 
The aim of this present study was to use observational data from the UK JSLE Cohort 
Study 1, to compare effectiveness of MMF vs. IVCYC induction treatments in patients 
with juvenile-onset LN, assessing response to treatment, damage accrual, time to 
achievement of inactive LN, and time to subsequent LN flare. 
 
Materials and methods 
Patients 
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Participants of the UK JSLE Cohort Study 1, recruited between 2006-2018, aged 16 
years at the time of diagnosis and with ≥4 American College of Rheumatology (ACR) 
SLE classification criteria were included in this study if they had biopsy proven 
proliferative ISN/RPS class III or IV LN 14. The majority of patients were recruited 
shortly after receiving a diagnosis of JSLE. However, at the time of the initial set-up of 
the cohort, previously diagnosed JSLE patients were recruited and retrospective data 
collected where possible.  Patients were excluded from the current study where there was 
only a single study visit, no date documented on the study forms for when for the renal 
biopsy was undertaken, or where there was inadequate clinical data to calculate a renal 
BILAG score at the time of renal biopsy or over the first year post biopsy.  The latter two 
exclusion criteria largely applied to patients who were diagnosed with JSLE prior 2006, 
when the UK JSLE Cohort started recruitment. 
 
Patients with class III and/or IV LN were grouped according to whether they received 
MMF or IVCYC as induction treatment. Concomitant corticosteroid treatment was also 
documented (oral prednisolone, IV methylprednisolone (IVMP) or both). Self-reported 
ethnicity information was collected in accordance with the UK National Census 
categories 15. Data from patients of mixed race were grouped with those of the associated 
ethnic minority group. Written patient assent/consent and parental consent was obtained 
to participate in the UK JSLE Cohort Study, and full ethical approval was in place from 
 9 
the National Research Ethics Service North West, Liverpool East, UK (reference 
06/Q1502/77). The research was carried out in accordance with the declaration of 
Helsinki. 
 
Clinical data for assessing response to treatment 
At a) baseline, b) 4-8, and c) 10-14 months post-biopsy, and d) the patient’s last visit, 
renal parameters (urine albumin:creatinine ratio, serum creatinine and the renal domain 
of the BILAG score), global disease activity parameters (erythrocyte sedimentation rate 
(ESR), anti-double stranded DNA antibodies (ds-DNA), complement factor 3 (C3)) and 
patient/physician global scores (both 0-100 scale) were collected.  
 
Assessment of LN disease activity and damage 
The British Isles Lupus Assessment Grade (BILAG) score is a composite disease activity 
measure focusing on nine organs/systems (constitutional, mucocutaneous, neurological, 
musculoskeletal, cardiovascular/respiratory, renal, gastrointestinal, opthalmic and 
haematological). The BILAG score focuses on capturing disease transitions, with the 
clinician being asked to grade clinical features as new, the same, worse or improving over 
the last 4 weeks and as compared to the preceding 4 weeks, facilitating accurate 
assessment of new activity, flare, or remission in individual organs/systems 16. The 
paediatric BILAG (pBILAG2004) has been adapted from the original adult BILAG score 
 10 
16 to include parameters of relevance to paediatric patients (e.g. normal blood pressure 
definitions), and has undergone validation in a UK paediatric cohort 17. 
 
The renal domain of the pBILAG2004 disease activity score 1 was used to assess LN 
disease activity longitudinally. It is calculated using information on proteinuria, blood 
pressure, serum creatinine, glomerular filtration rate (GFR), active urine sediment, and 
recent renal biopsy findings. The renal pBILAG score is graded A-E and defined as 
follows; pBILAG2004 grade A/B: severe, moderate disease respectively, grade C 
patients: mild/improving renal disease, grade D: inactive disease but previous system 
involvement, grade E: system has never been involved 16. The renal pBILAG score was 
used to define a change in LN activity; with attainment of inactive LN defined by the 
renal BILAG score changing from A, B or C to D; or subsequent flare following initial 
response to treatment defined by the renal pBILAG score changing from D to A or B. 
JSLE related damage was assessed using the Systemic Lupus International Collaborating 
Clinics Standardised Damage Index (SLICC-SDI) score 18 at 10-18 months post renal 
biopsy and last visit.  
 
Statistical analysis 
Renal parameters, laboratory markers of disease activity, renal pBILAG scores, 
patient/physician global scores and prednisolone dosage were compared between patients 
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who received MMF or IVCYC as induction treatment. Results are displayed as median 
values with interquartile ranges or counts and percentages. Since the data did not follow 
a normal distribution (Shapiro-Wilk test), non-parametric tests were employed. Mann-
Whitney U tests were used for continuous data and Fisher’s exact or Chi-squared tests for 
categorical data. All analysis was undertaken using PRISM version 6.0 software. 
 
Results 
At the time of data analysis (April 2018), the UK JSLE Cohort consisted of 411 patients 
meeting general inclusion criteria, with 69/411 (17%) experiencing proliferative LN 
(ISN/RPS class III or IV LN) during their disease course. Of these, 18/69 (29%) were 
excluded due to having only a single documented study visit (5/18 patients), or having 
insufficient clinical data at the time of their initial biopsy or over the first year of treatment 
(13/18 patients), leaving 51 patients who were subsequently considered (supplemental 
Table 1 displays the demographic details of the excluded patients). 34/51 (67%) received 
MMF (13/34 (38%) class III, 21/34 (62%) class IV LN), and 17/51 (33%) received 
IVCYC (8/17 (47%) class III, 9/17 (53%) class IV LN) as induction therapy (see Figure 
1).  
 
Of those individuals who received MMF induction treatment, 17/34 (50%) received 
concomitant oral prednisolone and the other 17/34 (50%) received both IVMP and oral 
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prednisolone. Within the IVCYC induction treatment group, 2/17 (12%) received oral 
prednisolone only and 15/17 (88%) received both IVMP and oral prednisolone. 32/34 
(94%) of LN patients who received MMF induction treatment continued on MMF 
maintenance treatment. No patients received concomitant Rituximab at induction. 8/17 
(47%) of those individuals who received IVCYC induction treatment subsequently 
received MMF maintenance treatment, 7/17 (41%) received azathioprine maintenance 
treatment and in 2/17 (12%) the maintenance treatment regimen was not documented.  
 
Baseline clinical and demographic factors 
There were no statistically significant differences between the groups receiving induction 
therapy with MMF or IVCYC in terms of clinical and demographic factors at baseline, 
including gender, ethnicity, age at diagnosis, age at LN onset, renal-pBILAG score, urine 
albumin/creatinine ratio, serum creatinine, ESR, anti-dsDNA antibody, C3 levels, 
patient/physician global scores and current prednisolone dosage (all p>0.05, see Table 
1). 
 
Response to treatment and damage accrual 
No statistically significant differences were identified between the MMF and IVCYC 
induction treatment groups at either 4-8, or 10-14 months post renal biopsy, and last 
follow-up, in terms of renal-pBILAG score, urine albumin/creatinine ratio, serum 
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creatinine, ESR, anti-dsDNA antibody, C3 levels, patient/physician global scores and 
current prednisolone dosage (all p>0.05, see Table 2). The last follow-up visit occurred 
after a median of 4.2 years [2.2-7.2] for the MMF treatment group and 3.3 years for the 
IVCYC group [2.1-5.3]. JSLE-related damage did not differ between treatment groups 
after a median of 13 months [range 10-18 months] post renal biopsy, with median SLICC-
SDI scores of 0 [0-1.0] in the MMF group, and 0 [0-2.5] in the IVCYC group (p = 0.67). 
Similarly, at the time of the last follow-up, no difference in SLICC-SDI scores were 
identified (MMF group = 1.0 [0-1.0], IVCYC group = 0 [0-2.5], p = 0.90, see Table 3). 
 
Time to achievement of inactive LN and subsequent flare 
A state of renal pBILAG-defined inactive LN (score = D) was reached in 29/34 (85%) 
patients who received MMF induction treatment and 14/17 (82%) patients who received 
IVCYC (p = 1.00). Inactive LN was achieved at a median of 8.5 months [4.5–12.6] after 
MMF treatment, and 4.9 months [3.8-9.8] following IVCYC treatment (p = 0.17). Similar 
proportions of patients experienced a subsequent LN flare (renal BILAG of D changed to 
A or B) regardless of the treatment group; 20/29 (69%) MMF treated and 7/14 (50%) 
IVCYC treated (p = 0.32). The time to subsequent flare was also comparable between 
the two patient groups; median of 14.5 months [5.1-40.8] for MMF treated, and 11.1 
months [6.4-20.5] for IVCYC treated patients (p = 0.47). 
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Discussion 
The aim of this study was to compare the effectiveness of MMF vs. IVCYC as induction 
treatments in children with LN, using data from the UK JSLE Cohort Study. Within the 
predominantly Caucasian JSLE study population, MMF and IVCYC had comparable 
efficacy with regards to treatment response, damage accrual, and time to next LN flare. 
Remission was reached sooner with IVCYC (median of 4.9 months following IVCYC 
and 8.5 months after MMF treatment). However, this did not reach statistical significance, 
warranting further analysis in larger studies. Of note, within this real-world UK-wide 
study, more patients received MMF than IVCYC as induction therapy for class III/IV LN 
(34/51 (67%) received MMF and 17/51 (33%) received IVCYC). The choice of LN 
induction treatment (MMF vs. IVCYC) was based upon individual physician’s choice, 
with no specific guidelines on paediatric LN treatment in the UK. More patients in the 
IVCYC group received IVMP at induction when compared to the MMF group. However, 
oral prednisolone doses were comparable between groups at all time-points.  
 
Results from the presented study highlight the need for a randomised and prospective 
comparison of MMF vs. IVCYC induction treatments, with strict steroid control between 
study arms, to better inform LN treatment protocols for children, especially given 
IVCYC’s poor safety profile 11, 12. Monitoring of serum MMF levels (e.g. through 
determination of AUC 19, with concentration-controlled dose adjustments is associated 
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with optimized mycophenolic acid exposure and an excellent renal outcome at 12 months 
of follow-up in a small sample of adult SLE patients with LN 20. Therefore, monitoring 
of MMF levels may be considered within such a prospective study. 
 
Observations of this study are complementary to findings reported by Lau et al. 10 who 
studied a much smaller cohort of American JSLE patients with class III LN (n=13), and 
demonstrated a comparable response following MMF or IVCYC induction treatment. The 
authors reported that 6 months after treatment initiation, no patient had achieved complete 
remission in the IVCYC group, while 57% were in partial remission. In the MMF group, 
66% had achieved complete remission, 17% were in partial remission, and 17% were not 
in remission, leading to the conclusion that MMF may be superior to IVCYC for the 
induction of remission in LN at 6 months. Although, small patient numbers precluded 
any meaningful statistical analysis. The current study differs from reports of Lau et al. in 
that both class III and IV LN patients were included, and patient numbers allowed 
meaningful statistical analyses. In this regard, data presented here also support the Single 
Hub and Access point for Paediatric Rheumatology in Europe (SHARE) LN 
recommendations to use MMF as an induction agent for LN 9. 
 
Results of the current study are also in-keeping with the reports from Appel et al. in adult 
SLE 12, the largest study to date comparing MMF vs. IVCYC induction treatment, albeit 
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in adult patients. It comprises a similar group of patients to the current study regarding 
race (US American; 39% White, 33% Asian, 27% ‘other race’ vs. 47% White, 35% Asian 
and 18% ‘other’ in the current UK JSLE Cohort Study). Also Appel et al. did not detect 
significant differences in renal response rates between IVCYC and MMF induction 
treatment 12. Furthermore, no differences were seen between the MMF and IVCYC 
groups in relation to adverse events, or infections. We are unable to comment on this 
within the current study, since these data are not collected within the UK JSLE Cohort 
Study.  
 
The study presented has several limitations which have to be considered. Despite being 
the largest JSLE study to date comparing response to MMF vs. IVCYC for LN induction 
treatment, patient numbers included are still relatively small. As per the inclusion criteria 
for this study, we only considered patients with class III or IV LN demonstrated on renal 
biopsy rather than all LN patients, for which these treatments are indicated, limiting the 
number LN patients available for inclusion. Unfortunately, almost one third of generally 
eligible patients had to be excluded, largely due to inadequate clinical data to calculate a 
renal BILAG score at baseline, or over the first year post renal biopsy. The UK JSLE 
Cohort Study collects patient data alongside routine clinical care. Therefore, reported 
clinical parameters, patient/physician global scores, treatment details and SDI damage 
data are recorded over a range of follow-up times post biopsy, rather than at exact 
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predetermined time points.  Lastly, the length of follow-up varied somewhat between 
patient groups, with MMF treated patients being followed for a median of 4.2 years [IQR 
2.2-7.2] and IVCYC patients for 3.3 years [2.1-5.3] (although this did not reach statistical 
significance).  
 
The UK JSLE Cohort Study does not collect sufficient data to rigorously compare safety 
profiles of CYC vs. MMF treatments. In light of these limitations, prospective 
comparison of MMF vs. IVCYC induction treatment in larger, ethnically diverse JSLE 
cohorts, whilst monitoring treatment adherence (e.g. MMF levels) and drug safety data, 
would better inform treatment decisions for patients with LN. 
 
Conclusions 
This is the largest study to date investigating induction treatments for proliferative LN in 
JSLE. In a predominantly Caucasian JSLE populations, MMF and IVCYC appear to be 
comparably efficacious in regard to treatment response, damage accrual, and time to next 
flare. Randomized and prospective comparison of MMF vs. IVCYC treatment is 
warranted in ethnically diverse international JSLE cohorts to inform LN treatment 
protocols, and to explore the relative safety of both treatment regimens. 
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Table 1: Demographic and clinical details of the MMF and IVCYC treated groups 
at baseline 
Demographics MMF induction 
(n=34) 
IVCYC induction 
(n=17) 
p-value 
Gender F = 27 (79%)  
M = 7 (21%) 
F = 14 (82%) 
M = 3 (18%) 
1.0 
Race 
 White British 
 Asiana 
 African / Caribbeanb 
 Other Caucasian origin 
 
16 (47%) 
11 (32%) 
6 (18%) 
1 (3%) 
 
8 (47%) 
7 (41%) 
1 (6%) 
1 (6%) 
 
 
0.81 
Age at diagnosis (years) 12.6 [9.0-14.8] 13.3 [12.1-15.1] 0.10 
Age at biopsy (years) 13.3 [11.2-15.0] 13.6 [12.8-15.6] 0.20 
Renal pBILAG score A – 9 
B – 11 
C – 1 
D – 6 
A – 4 
B – 7 
C – 2 
D – 2 
0.69 
Urine albumin / creatinine 
ratio (mg/mmolCr) 
45.5 [17.7-138.0] 177.8 [15.5-719.8] 0.16 
 23 
Serum creatinine (mol/l) 63.0 [51.0-137.0] 72.0 [ 57.8-101.5] 0.18 
Patient global (0-100) 20.0 [2.0-25.0] 23.5 [0.0-55.5] 0.86 
Physician global (0-100) 34.0 [11.0-50.0] 31.5 [9.4-40.0] 0.82 
ESR (mm/h) 41.0 [11.0-80.0] 25.0 [10.0-56.75] 0.64 
dsDNA (IU/l) 77.5 [26.5-270] 226.0 [200-400] 0.15 
C3 (g/L) 0.86 [0.54-1.14] 0.85 [0.34-1.31] 0.81 
Current prednisolone dose 
(mg) 
28 [14-40] 25 [20-53] 0.47 
aAsian origin included Bangladeshi, Indian and Pakistani patients.   bAfrican/Caribbean 
included patients of African, Caribbean, mixed White and Black African and mixed 
White and Caribbean origin. Counts and percentages or median values with interquartile 
ranges displayed. Mann-Whitney U tests used for continuous data Chi-squared tests for 
categorical data. Fishers exact test utilised to compare the proportion of active LN (renal 
paediatric British Isles Lupus Assessment Grade (pBILAG) domain A, B or C) to inactive 
LN patients (renal-pBILAG domain of D). MMF, Mycophenolate Mofetil. IV, intra-
venous. CYC, Cyclophosphamide. F, female. M, male. ACR, American College of 
Rheumatology. ESR, erythrocyte sedimentation rate. DsDNA, anti-double stranded DNA 
antibodies. C3, complement factor 3. 
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Table 2: Comparison of JSLE clinical parameters and patient/physician global 
scores following MMF vs. IVCYC treatment. 
Time 
post 
biopsy 
Outcome parameter MMF treated 
 
IVCYC treated 
 
p-value 
4-8 
months 
Renal pBILAG scorea A – 3 (12%) 
B – 9 (35%) 
C – 3 (12%) 
D – 11 (41%) 
A – 2 (14%) 
B – 2 (14%) 
C – 4 (28%) 
D – 6 (44%) 
1.0 
Urine albumin / 
creatinine ratio 
(mg/mmolCr) 
27 [12.8 – 96.4] 9 [1.3 – 67] 0.46 
Serum creatinine (mol/l) 60.0 [47.5 – 75.0] 59.5 [49.8 – 75.0] 0.86 
Patient global (0-100) 10 [0 – 47.0] 16 [0 – 32.2] 0.71 
Physician global (0-100) 11 [1.5 - 25.5] 7.8 [5.0 – 31.5] 0.71 
ESR (mm/h) 10.5 [3.3-20.8] 23.5 [10.8 – 77.8] 0.07 
dsDNA (IU/l) 54.0 [29.6 – 88.9] 81.5 [0 – 270.0] 0.84 
C3 (g/L) 1.04 [0.87 -1.32] 0.88 [0.78 – 0.99] 0.08 
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Current prednisolone 
dose (mg) 
10 [10-15] 13 [8-23] 0.48 
10-14 
months 
Renal pBILAG scoreb A – 1 (4%) 
B – 5 (19%) 
C – 3 (11%) 
D – 18 (66%) 
A – 1 (7%) 
B – 3 (21%) 
C – 2 (14%) 
D – 8 (58%) 
1.00 
Urine albumin / 
creatinine ratio 
(mg/mmolCr) 
13.25 [4.3 – 41.7] 20.5 [ 3.0 – 56.4] 0.99 
Serum creatinine (mol/l) 59 [51.0 – 69.0] 62.0 [50.0 – 73.0] 0.33 
Patient global (0-100) 4.5 [0 – 9.3] 3.0 [0.5 – 52.0] 0.98 
Physician global (0-100) 7.0 [1.3 – 14.0] 9.9 [3.0 – 24.0] 0.66 
ESR (mm/h) 11.5 [5.0 – 20.8] 20.0 [4.0 – 48.5] 0.62 
dsDNA (IU/l) 44.0 [24.0 – 94.8] 20.4 [6.4 – 439.5] 0.84 
C3 (g/L) 0.98 [0.81 – 1.18] 1.04 [0.92 – 1.34] 0.21 
Current prednisolone 
dose (mg) 
9 [5-10] 7 [4-14] 0.89 
Last visit 
Renal pBILAG scorec A – 1 (3%) 
B – 5 (16%) 
A – 1 (7%) 
B – 1 (7%) 
1.0 
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C – 3 (9%) 
D – 23 (72%) 
C – 2 (14%) 
D – 11 (72%) 
Urine albumin / 
creatinine ratio 
(mg/mmolCr) 
21.0 [6.0 – 42.0] 17.4 [8.0 – 116.9] 0.81 
Serum creatinine (mol/l) 54.0 [46.0 – 59.0] 62.0 [50.5 – 74.8] 0.08 
Patient global (0-100) 8.0 [0.0 – 30.0] 2.0 [0.0 – 52.0] 0.75 
Physician global (0-100) 4.0 [0.0 – 15.0] 4.0 [0.0 – 23.5] 0.56 
ESR (mm/h) 6.0 [3.0 -20.0] 15.0 [5.5 – 52.0] 0.09 
dsDNA (IU/l) 51.3 [15.5 – 
150.5] 
14.5 [5.4 – 129.8] 
0.28 
C3 (g/L) 1.06 [0.92 – 1.24] 1.14 [0.83 – 1.21] 0.94 
 
Current prednisolone 
dose (mg) 
7 [5-9] 10 [5-20] 0.42 
aSufficient clinical data available to calculate the renal-pBILAG score in 26/34 MMF, 
and 14/17 CYC treated patients. Fishers exact test utilised to compare the proportion of 
active LN (renal-pBILAG domain A, B or C) to inactive LN patients (renal-pBILAG 
domain of D). bSufficient data to calculate the renal-pBILAG score in 27/34 MMF treated 
and 14/17 CYC treated patients. cSufficient clinical data to calculate the renal-pBILAG 
score in 32/34 MMF treated and 15/17 CYC treated patients. Median values/inter-quartile 
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ranges quoted for clinical parameters and patient/physician global scores. 
Counts/percentages given for renal-pBILAG scores. Mann-Whitney U test used to 
compare the treatment groups. MMF, Mycophenolate Mofetil. IV, intra-venous. CYC, 
Cyclophosphamide. pBILAG, paediatric British Isles Lupus Assessment Grade. F, 
female. M, male. ACR, American College of Rheumatology. ESR, erythrocyte 
sedimentation rate. DsDNA, anti-double stranded DNA antibodies. C3, complement 
factor 3. 
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Table 3: SLICC SDI damage scores at 10-18 months post renal biopsy and last 
follow-up visit. 
Time 
SLICC SDI 
p-value 
MMF IVCYC 
10-18 months post biopsya 0 [0 - 1] 0 [0 – 2.5] 0.67 
Last follow-upb 1.0 [0 – 1] 0 [0 – 2.5] 0.90 
aSLICC SDI data available for 40/51 patients at 10-18 months post biopsy. bSLICC SDI 
data available for all 51 patients at last follow-up. Median values and inter-quartile 
ranges quoted, with Mann Whitney U test used to compare the treatment groups. 
SLICC-SDI, Systemic Lupus International Collaborating Clinics Standardised Damage 
Index score. MMF, Mycophenolate Mofetil. IV, intra-venous. CYC, 
Cyclophosphamide. 
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Supplemental Table 1: Demographic details of the excluded patients 
Gender F = 14 (77%)  
M =  4 (23%) 
Race 
 White British 
 Asiana 
 African / Caribbeanb 
 Other Caucasian origin 
 
9 (50%) 
5 (27%) 
3 (17%) 
1 (6%) 
Age at diagnosis (years) 11.0 [9.0-13.0] 
Age at biopsy (years)c 12.1 [10.3-14.1] 
aAsian origin included Bangladeshi, Indian and Pakistani patients.   bAfrican/Caribbean 
included patients of African, Caribbean, mixed White and Black African and mixed 
White and Caribbean origin. Counts and percentages or median values with interquartile 
ranges displayed. cAge at biopsy data not available for 3 patients. 
 
 
 
